NCT07223658

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Phase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: Arrowhead Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.

Conditions

• Hyperlipidemia; Mixed

Interventions

Type	Name	Description
DRUG	ARO-DIMERPA	Subcutaneous (SC) injection
DRUG	Placebo	Calculated volume to match active treatment by SC injection

Timeline

• Start date: 2025-12-22
• Primary completion: 2026-06-01
• Completion: 2027-07-01
• First posted: 2025-11-03
• Last updated: 2026-01-09

Locations

1 site across 1 country: New Zealand

Regulatory

• FDA-regulated drug study